文献速递胸部肿瘤

纳武利尤单抗对比多西他赛治疗经治晚期非小细胞肺癌的两年结局

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
PubMed 文献 · J Clin Oncol · 2017-10-12

CheckMate 017和057两项III期随机开放标签试验报告至少随访24.2个月的更新结果及汇总分析。纳武利尤单抗对比多西他赛的2年总生存率在鳞癌为23%对8%,非鳞癌为29%对16%,汇总分析中死亡风险相对降低28%(HR 0.72,95%CI 0.62-0.84),治疗相关不良事件发生率更低。

要点

  • 鳞癌2年总生存率纳武利尤单抗23% vs 多西他赛8%;非鳞癌29% vs 16%。
  • 汇总分析死亡风险相对降低28%(HR 0.72,95%CI 0.62-0.84)。
  • 纳武利尤单抗组有持续缓解,多西他赛组无持续缓解;不良事件更少。

核心结论

  • 在经治晚期NSCLC患者中,纳武利尤单抗对比多西他赛提供长期临床获益和良好耐受性。

研究设计与样本

  • 两项独立III期随机开放标签试验(CheckMate 017鳞癌N=272,CheckMate 057非鳞癌N=582)的更新结果及汇总分析。
  • 患者为IIIB/IV期NSCLC且既往铂类化疗期间或之后进展,按1:1随机分配至纳武利尤单抗(3 mg/kg每2周)或多西他赛(75 mg/m2每3周)。
  • 生存最低随访时间为24.2个月。

主要发现

  • 鳞癌NSCLC中纳武利尤单抗对比多西他赛的2年总生存率为23%(95%CI 16%-30%) vs 8%(95%CI 4%-13%)。
  • 非鳞癌NSCLC中纳武利尤单抗对比多西他赛的2年总生存率为29%(95%CI 24%-34%) vs 16%(95%CI 12%-20%)。
  • 纳武利尤单抗对比多西他赛的死亡风险相对降低与主要分析相似;鳞癌27例确认缓解者中10例(37%)、非鳞癌56例中19例(34%)在至少2年随访后仍有持续缓解;多西他赛组无患者有持续缓解。
  • 汇总分析中纳武利尤单抗对比多西他赛的死亡风险相对降低28%(HR 0.72,95%CI 0.62-0.84)。
  • 治疗相关不良事件发生率纳武利尤单抗低于多西他赛:任何级别68% vs 88%;3-4级10% vs 55%。

关键数值与推荐

  • 纳武利尤单抗剂量为3 mg/kg每2周;多西他赛剂量为75 mg/m2每3周。
  • 鳞癌2年总生存率:纳武利尤单抗23%(95%CI 16%-30%) vs 多西他赛8%(95%CI 4%-13%)。
  • 非鳞癌2年总生存率:纳武利尤单抗29%(95%CI 24%-34%) vs 多西他赛16%(95%CI 12%-20%)。
  • 汇总死亡风险相对降低28%(HR 0.72,95%CI 0.62-0.84)。
  • 治疗相关不良事件:任何级别纳武利尤单抗68% vs 多西他赛88%;3-4级10% vs 55%。

临床怎么用

  • 在既往铂类化疗后进展的晚期鳞癌或非鳞癌NSCLC患者中,纳武利尤单抗对比多西他赛显示长期生存获益和更低的治疗相关不良事件发生率。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or nonsquamous (CheckMate 057; ClinicalTrials.gov identifier: NCT01673867) non-small-cell lung cancer (NSCLC). We report updated results, including a pooled analysis of the two studies. Methods Patients with stage IIIB/IV squamous (N = 272) or nonsquamous (N = 582) NSCLC and disease progression during or after prior platinum-based chemotherapy were randomly assigned 1:1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m2 every 3 weeks). Minimum follow-up for survival was 24.2 months. Results Two-year overall survival rates with nivolumab versus docetaxel were 23% (95% CI, 16% to 30%) versus 8% (95% CI, 4% to 13%) in squamous NSCLC and 29% (95% CI, 24% to 34%) versus 16% (95% CI, 12% to 20%) in nonsquamous NSCLC; relative reductions in the risk of death with nivolumab versus docetaxel remained similar to those reported in the primary analyses. Durable responses were observed with nivolumab; 10 (37%) of 27 confirmed responders with squamous NSCLC and 19 (34%) of 56 with nonsquamous NSCLC had ongoing responses after 2 years' minimum follow-up. No patient in either docetaxel group had an ongoing response. In the pooled analysis, the relative reduction in the risk of death with nivolumab versus docetaxel was 28% (hazard ratio, 0.72; 95% CI, 0.62 to 0.84), and rates of treatment-related adverse events were lower with nivolumab than with docetaxel (any grade, 68% v 88%; grade 3 to 4, 10% v 55%). Conclusion Nivolumab provides long-term clinical benefit and a favorable tolerability profile compared with docetaxel in previously treated patients with advanced NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Horn L, Spigel DR, Vokes EE, et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017. PMID: 29023213. doi:10.1200/JCO.2017.74.3062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。